

1

2

## Supporting Information

3

4

5 **Heterozygous mutation in *BRCA2* induces accelerated age-**  
6 **dependent decline in sperm quality with male subfertility in rats**

7

8

9 Yashiro Motooka, Hideaki Tanaka, Yuki Maeda, Misako Katabuchi, Tomoji Mashimo,

10 Shinya Toyokuni

11

12

13

14 **Supporting Tables**

15 Table S1. Summary of primers for PCR

16 Table S2. Summary of the antibodies used in this study

17 Table S3. Criteria for Johnsen's score

18

19 **Supporting Figures**

20 Figure S1. Sanger sequencing shows no mutation in the regions of potential off-target  
21 effects

22 **Figure S2. Metaphase spermatocytes in *Brca2*<sup>wt/mut</sup> testes exhibited lower staining  
23 intensity for BRCA2 and phosphorylated BRCA2 in immunohistochemistry compared  
24 to *Brca2*<sup>wt/wt</sup>**

25 Figure S3. Uncropped images of membranes used for immunoblotting

26 Figure S4. Immunohistochemistry shows no significant differences in oxidative stress  
27 markers, 8-OHdG and 4-HNE, in the testes of *Brca2*<sup>wt/mut</sup> rat at 11 weeks

28 **Figure S5. Representative images of TUNEL staining for each main stage of  
29 seminiferous tubules**

30 Figure S6. Representative plots of SCSA

31

32 **Table S1. Summary of primers for PCR**

33

Target name	Primer type	Primer name	Target information	The primer sequence from 5' end to 3' end	Length	Tm value	GC content (%)
<i>Brca2</i> wild type	Forward	<i>Brca2</i> -F	Wild type allele	CCAAAGTGTGTCTGGACTGAAG	22	59.8	50
<i>Brca2</i> wild type	Reverse	<i>Brca2</i> -R	Wild type allele	ATTCTGGGGTTCTGCTTTCA	20	59.7	45
Founder No.18 and 27	Forward	<i>Brca2</i> -MUT-F	Newly formed nucleotide sequence	CATCCTTCACGCAAGTGG	18	57.6	55.56
<i>Brca2</i> wild type	Forward	<i>Brca2</i> -F2	Nucleotide sequence commonly deleted in this genome editing	CGCACTTATGGAATTTTAGCAC	23	60	39.1
Founder No3	Forward	<i>Brca2</i> -F3d8-F	Newly formed nucleotide sequence	AGGAAGTCCATCCTTCATGG	20	58.5	50
Inframe deletion of Founder No6, 7, 9, and 19	Forward	<i>Brca2</i> -F6d18-F	Newly formed nucleotide sequence	ATCCTTCACGCACAGCAAG	19	60	52.63
Founder No6	Forward	<i>Brca2</i> -F6d17-F	Newly formed nucleotide sequence	CAGGAAGTCCATCCTTTTAGC	22	58.4	45.45
Founder No7	Forward	<i>Brca2</i> -F7d20a1-F	Newly formed nucleotide sequence	ATCCTTCACGCACACAAG	18	56.9	50
Founder No9	Forward	<i>Brca2</i> -F9d50-F	Newly formed nucleotide sequence	GGAAACTTGGGATACATGGAA	21	57.2	42.86
Founder No16	Forward	<i>Brca2</i> -F16d299-F	Newly formed nucleotide sequence	TCCATCCTTCACGCACTTAC	20	59.2	50
Inframe deletion of Founder No19	Forward	<i>Brca2</i> -F19d18-F	Newly formed nucleotide sequence	TCCATCCTTCACGCAAGTG	19	59.4	52.63
Founder No19	Forward	<i>Brca2</i> -F19d50-F	Newly formed nucleotide sequence	GGGATACATGTAATTTTAGCACAGC	26	60.1	38.46
Founder No24-1	Forward	<i>Brca2</i> -F24d9a1-F	Newly formed nucleotide sequence	CATCCTTCACGCACATTTTAGC	22	59.7	45.45
Founder No24-2	Forward	<i>Brca2</i> -F24d17-F	Newly formed nucleotide sequence	CAGGAAGTCCAGAATTTTAGCAC	24	59.4	41.67
Founder No26-1	Forward	<i>Brca2</i> -F26d6-F	Newly formed nucleotide sequence	AAGTCCATCCTTCACGTGG	19	58.8	52.63
Founder No26-2	Forward	<i>Brca2</i> -F26d13-F	Newly formed nucleotide sequence	CCATCCTTCATTTTAGCACAGC	23	59.8	43.48
Founder No27	Forward	<i>Brca2</i> -F27d23-F	Newly formed nucleotide sequence	TTCACGCAAGTGGAAAAGC	19	58.5	47.37
Off target 1	Forward	Fot1	Possible off target site 1	TAAGAGATGTTCTTCCACTCCTAATC	27	59.9	40.74
Off target 1	Reverse	Rot1	Possible off target site 1	GCACATGATCAGCATCTACACATC	24	60.0	45.83
Off target 2	Forward	Fot2	Possible off target site 2	CAGATTGGACTGTACTGACCTTGTG	25	61.3	48.00
Off target 2	Reverse	Rot2	Possible off target site 2	GTGTATAGTACAGGGTGTGTTTCAGGAG	28	62.8	46.43

34

35 **Table S2. Summary of the antibodies used in this study**

36

Target molecule [clone]	Immunized host	Supplier	Ordering Number	Antigen retrieval	Dilution for IHC	Dilution for immunoblotting
BRCA2 (aa 1-100)	Rabbit	abcam	ab216972	ER1 10 min	1:1,000	1:1000
BRCA2 (E2070- S2120)	Rabbit	Invitrogen	PA5- 105731	ER1 10 min	1:1,000	1:1000
Phosphorylated BRCA2	Rabbit	Invitrogen	PA5- 105585	ER1 10 min	1:1,000	1:1000
DDX4 / MVH [RM1022]	Rabbit	abcam	ab284611	ER1 10 min	1:1,000	
$\gamma$ H2AX [JBW301]	Mouse	Merck	05-636	ER1 10 min	1:500	
8-OHdG [N45.1]	Mouse	In house (26)		ER1 10 min	1:8,000	
4-HNE [HNE-J2]	Mouse	In house (27)		ER1 10 min	1:20,000	
$\beta$ -actin [AC-15]	Mouse	Sigma- Aldrich	A1978			1:2000

37

38


39 **Table S3. Criteria for Johnsen's score**  
 40

Johnsen's score	Pathological findings
Score 10	Complete spermatogenesis with spermatozoa. (Spermatozoa are here defined as cells having achieved the small head form of the spermatozoon). Germinal epithelium organized in a regular thickness leaving an open lumen.
Score 9	Many spermatozoa present but germinal epithelium disorganized with marked sloughing or obliteration of lumen.
Score 8	Only few spermatozoa (<5-10) present in section
Score 7	No spermatozoa but many spermatids present.
Score 6	No spermatozoa and only few spermatids (<5-10) present.
Score 5	No spermatozoa, no spermatids but several or many spermatocytes present.
Score 4	Only few spermatocytes (<5) and no spermatids or spermatozoa present.
Score 3	Spermatogonia are the only germ cells present.
Score 2	No germ cells but Sertoli cells are present.
Score 1	No cells in tubular section.


41

42 **Figure S1. Sanger sequencing shows no mutation in the regions of potential off-target**  
 43 **effects**

**a** First candidate site for off-target effects: chr5; 122,278,836 - 122,278,850



**b** Second candidate site for off-target effects: chr6; 31,224,278 - 31,224,292




**Figure S1**

45 **Figure S1. Sanger sequencing shows no mutation in the regions of potential off-target**  
46 **effects**

47 (a, b) Two candidate sites for off-target effects caused by this genome editing, detected by  
48 CRISPRdirect, along with the Sanger sequencing results for the surrounding regions of  
49 each site. The results of Sanger sequencing are compared with the sequence of the wild-  
50 type SD rat. The upper row represents the wild type, and the lower row is from the  
51 founder rat with *Brca2* p.T1942Kfs\*8 allele. (a) Possible off-target region on chromosome  
52 5. (b) Possible off-target region on chromosome 6.

53

54 **Figure S2. Metaphase spermatocytes in *Brca2*<sup>wt/mt</sup> testes exhibits lower staining**  
 55 **intensity for BRCA2 and phosphorylated BRCA2 in immunohistochemistry compared**  
 56 **to *Brca2*<sup>wt/wt</sup>**



**Figure S2**



58 **Figure S2. Metaphase spermatocytes in *Brca2*<sup>wt/mt</sup> testes exhibits lower staining**  
59 **intensity for BRCA2 and phosphorylated BRCA2 in immunohistochemistry compared**  
60 **to *Brca2*<sup>wt/wt</sup>**

61 (a, b) Typical microscopic imaged and staining intensity analysis of metaphase  
62 spermatocytes immunostained for (a) BRCA2 or (b) pBRCA2. In each case, 5 rats aged 11  
63 weeks were evaluated. For each individual, 4-5 images were captured randomly at x20  
64 magnification, ensuring inclusion of metaphase spermatocytes. From these images, five  
65 seminiferous tubules were selected, and two metaphase cells were chosen within circular  
66 ROIs (yellow circles). Subsequently, color deconvolution for DAB was performed, and  
67 staining intensity of DAB within each ROI was measured. Quantitative results from 10  
68 metaphase spermatocytes per individual were summed to calculate the distribution of  
69 staining intensity. The average distribution ratio for each individual within the group is  
70 presented here. Both BRCA2 and pBRCA2 were stained weaker in *Brca2*<sup>wt/mt</sup> rats  
71 compared to *Brca2*<sup>wt/wt</sup>. DAB: Diaminobenzidine; ROI: region of interest.

72

73

74


75

76

77

78

79 **Figure S3. Uncropped images of membranes used for immunoblotting.**



**Figure S3**

80


81

82

83 **Figure S3. Uncropped images of membranes used for immunoblotting**

84 (a-f) Uncropped band patterns and the figures merged with macroscopic images from  
85 immunoblotting analysis with antibodies against BRCA2 (aa 1-100), BRCA2 (E2082-  
86 L2106), phosphorylated BRCA2 (Ser2095,) and  $\beta$ -actin. Human cell lines, HOSE1C and  
87 OV90, lacking *BRCA2* mutations, are used for size reference. After evaluating BRCA2 (aa  
88 1-100) (a), stripping was performed, and the removal of the antibody was confirmed to be  
89 enough (b). Subsequently, the same membrane was used to assess BRCA2 (E2082-L2106)  
90 and  $\beta$ -actin (c, d). Expression of BRCA2 and phosphorylated BRCA2 are slightly  
91 decreased in *Brca2*<sup>wt/mut</sup> testes without truncated or splicing variants.

92 **Figure S4. Immunohistochemistry shows no significant differences in oxidative stress**  
 93 **markers, 8-OHdG and 4-HNE, in the testes of Brca2wt/mut rat at 11 weeks**



**Figure S4**


94 **Figure S4. Immunohistochemistry shows no significant differences in oxidative stress**  
95 **markers, 8-OHdG and 4-HNE, in the testes of Brca2wt/mut rat at 11 weeks**

96 (a, b) Representative immunostaining images of testes from 11-week-old rats using (a) 8-  
97 OHdG and (b) 4-HNE antibody, and quantitative analysis of these staining in  
98 spermatocytes within stage VI-VIII and stage IX-XIV seminiferous tubules (n = 5). These  
99 makers of oxidative stress exhibited no significant differences between *Brca2*<sup>wt/wt</sup> and  
100 *Brca2*<sup>wt/mut</sup> rats (bar = 100 μm).

101

102 **Figure S5. Representative images of TUNEL staining for each main stage of**  
103 **seminiferous tubules**

104



**Figure S5**

105

106 **Figure S5. Representative images of TUNEL staining for each main stage of**  
107 **seminiferous tubules**

108 (a-c) Typical images from TUNEL staining of seminiferous tubules from *BRCA2*<sup>wt/mut</sup> rats.


109 (a) In stage I-VII seminiferous tubules, spermatogonia with flat nuclei form a layer at the  
110 base, with a single layer of transition-form spermatocytes above them. Transition-form  
111 spermatocytes exhibit round nuclei, which are strongly stained by Hoechst 33342. Toward  
112 the luminal side, multiple layers of spermatids with small nuclei are observed. In the left  
113 image, transition-form spermatocytes and spermatid are TUNEL-positive whereas in the  
114 right image, spermatogonia, transition-form spermatocyte and spermatids are TUNEL-  
115 positive. (b) In stage VIII seminiferous tubules, spermatogonia with flat nuclei and resting  
116 spermatocytes with oval nuclei form a layer directly above the basement membrane.  
117 Toward the luminal side, a single layer of pachytene spermatocytes with round and  
118 slightly larger nuclei is distributed. Further toward the lumen, multiple layers of  
119 spermatids are observed. Here, in both images, spermatids are TUNEL-positive. (c) In  
120 stage IX-XIII seminiferous tubules, spermatogonia with flat nuclei are positioned on the  
121 basement membrane, with a single layer of leptotene spermatocytes located toward the  
122 lumen. Further toward the lumen, pachytene spermatocytes with enlarged nuclei are  
123 present in multiple layers, intermixed with small-nucleus spermatids. In the left image,  
124 leptotene and pachytene spermatocytes are TUNEL-positive whereas in right image,  
125 spermatogonia and leptotene spermatocytes are TUNEL-positive. R, resting  
126 spermatocytes; L, leptotene; T, transition form; P, pachytene.

127

128

129 **Figure S6. Representative plots of SCSA**

130



**Figure S4**

131

132

133



**134 Figure S6. Representative plots of SCSA**

135 Representative plots of SCSA performed on spermatozoa from *Brca2*<sup>wt/wt</sup> or *Brca2*<sup>wt/mut</sup> rats  
136 at the age of 11 weeks and 8 months. These plots indicate that spermatozoa from  
137 *Brca2*<sup>wt/mut</sup> contain a higher proportion of DNA fragmentation than those from *Brca2*<sup>wt/wt</sup>  
138 both at both 11 weeks and 8 months. In SCSA, the Acridine Orange (AO) equilibration  
139 buffer [400- $\mu$ l acid detergent solution (0.08N HCl, 0.15M NaCl, 0.1% Triton X-100, pH  
140 1.20) mixed with 1,200- $\mu$ l AO staining solution (0.0006% AO, 0.1 M citric acid buffer, 0.2  
141 M Na<sub>2</sub>PO<sub>4</sub>, DW)] was circulated in the flow cytometer's fluidic system for more than 15  
142 min before evaluating the samples. Ten thousand events were recorded. The analysis was  
143 conducted in accordance with established protocols<sup>56</sup>. Briefly, AO-stained spermatozoa  
144 sample was inserted into the flow cytometer, in which the green and red fluorescence  
145 gains of the flow cytometer was adjusted so that the primary group of AO-green  
146 fluorescence nearly reaches the halfway up the Y-axis (green) whereas the AO-red  
147 fluorescence approximates 1/5 of the total X-axis (red). Then, gates were set up to identify  
148 spermatozoa with fragmented DNA, by drawing a horizontal gate along the top edge of  
149 the main cigar-shaped spermatozoa population, creating a straight gate on the right side  
150 of the cigar-shaped normal spermatozoa population, and making a 45-degree angled gate  
151 that intersects the lower boundary of the main cigar-shaped population to exclude  
152 apoptotic and dead spermatozoa along with other seminal debris. Spermatozoa with  
153 fragmented DNA are located in the area to the right of the main population, which  
154 includes the cigar-shaped plots. DNA fragmentation index (%DFI) was calculated via  
155 dividing the number of spermatozoa with fragmented DNA by the total number of  
156 spermatozoa. AO, Acridine Orange; SCSA, sperm chromatin structure assay; %DFI, %  
157 DNA fragmentation index.